EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieKohortenstudieOpen Access

Real-World Evidence for Oncology Patients With Rare NTRK Gene Fusions: Final Results From the German Multicenter Patient Cohort Study REALTRK

Karin Potthoff iD, Sebastian Lange iD, Thomas Seufferlein iD, Kathrin Heinrich iD, Rainer Claus iD, Annalen Bleckmann iD, Matthias Zaiss, Corinne Vannier, Sina Grebhardt, Sophie Koszinowski, Larissa E Hillebrand, Kai Ringwald iD und 1 weitere

JCO Precision Oncology · 2026-08 · 10 (8)

DOI: 10.1200/po-26-00283 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Precision Oncology, 2026-08. Verfasst von Karin Potthoff und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medical Department, iOMEDICO, Freiburg, Germany. Hauptthemen laut MEDLINE: Neoplasms, Protein Kinase Inhibitors, Receptor, trkA, Receptor, trkC. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE TRK inhibitors (TRKis) have transformed the therapeutic landscape for patients with neurotrophic tyrosine receptor kinase ( NTRK ) gene fusion–positive tumors. However, approval of TRKis is based on evidence derived mainly from small, pooled, single-arm clinical trial cohorts. The REALTRK registry aims to describe real-world molecular diagnostic practices, treatment patterns, and clinical outcomes for adult patients with NTRK fusion–positive cancers. PATIENTS AND METHODS The REALTRK registry was a multicenter cohort study that included adults with advanced solid tumors harboring NTRK1 / 2 / 3 fusions, from Germany and Switzerland. Both retrospective and prospective data were collected from diverse clinical settings. NTRK fusions had to be diagnosed via validated assays. RESULTS Of 88 patients screened, 47 adults with advanced NTRK fusion–positive solid tumors were included in the full analysis set. Across all treatment lines after NTRK fusion diagnosis, 29 patients received TRKi therapy, eight received non-TRKi therapy, and 10 received no therapy. Lung cancer, colorectal cancer, and soft tissue sarcoma were the most common tumor types. Next-generation sequencing was the primary diagnostic method, with a median turnaround time of 2 weeks. After NTRK fusion diagnosis, TRKi therapy was immediately initiated in 26 patients, of whom 13 received TRKi as first-line treatment in the advanced/metastatic setting. About half of the patients responded to TRKi treatment as the first treatment line after NTRK fusion diagnosis (46.2%), with an overall response rate of 46.2% and a disease control rate of 73.1%. The median progression-free survival was 15.7 months, and the overall survival was 27.6 months in TRKi-treated patients. CONCLUSION The REALTRK registry provides important real-world insights into the patient path of adult patients with locally advanced or metastatic solid tumors harboring NTRK1 / 2 / 3 gene fusions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsProtein Kinase InhibitorsReceptor, trkAReceptor, trkCAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedCohort StudiesGermanyProspective StudiesReceptor, trkBRegistriesRetrospective Studies

Substanzen

NTRK1 protein, humanNTRK3 protein, humanProtein Kinase InhibitorsReceptor, trkAReceptor, trkBReceptor, trkC

Autor:innen und Institutionen

  • Medical Department, iOMEDICO, Freiburg, Germany.
  • Clinical Department of Internal Medicine II, TUM School of Medicine and Health, TUM University Hospital, Munich, Germany.
  • Center for Personalized Medicine, TUM School of Medicine and Health, TUM University Hospital, Munich, Germany.
  • Universitätsklinikum Ulm, Klinik für Innere Medizin I, Ulm, Germany.
  • LMU Klinikum, Medizinische Klinik und Poliklinik III, München, Germany.
  • University of Augsburg, Faculty of Medicine, Comprehensive Cancer Center Augsburg (CCCA), Augsburg, Germany.

ORCID-Profile: Karin Potthoff, Sebastian Lange, Thomas Seufferlein, Kathrin Heinrich, Rainer Claus, Annalen Bleckmann, Kai Ringwald

Zitieren

APA

Potthoff, K., Lange, S., Seufferlein, T., Heinrich, K., Claus, R., Bleckmann, A., Zaiss, M., Vannier, C., Grebhardt, S., Koszinowski, S., Hillebrand, L. E., Ringwald, K., & Kasenda, B. (2026). Real-World Evidence for Oncology Patients With Rare NTRK Gene Fusions: Final Results From the German Multicenter Patient Cohort Study REALTRK. JCO Precision Oncology, 10(8). https://doi.org/10.1200/po-26-00283

Vancouver

Potthoff K, Lange S, Seufferlein T, Heinrich K, Claus R, Bleckmann A, et al. Real-World Evidence for Oncology Patients With Rare NTRK Gene Fusions: Final Results From the German Multicenter Patient Cohort Study REALTRK. JCO Precision Oncology. 2026;10(8). doi:10.1200/po-26-00283

BibTeX
@article{Potthoff2026,
  author = {Potthoff, Karin and Lange, Sebastian and Seufferlein, Thomas and Heinrich, Kathrin and Claus, Rainer and Bleckmann, Annalen and Zaiss, Matthias and Vannier, Corinne and Grebhardt, Sina and Koszinowski, Sophie and Hillebrand, Larissa E and Ringwald, Kai and Kasenda, Benjamin},
  title = {Real-World Evidence for Oncology Patients With Rare NTRK Gene Fusions: Final Results From the German Multicenter Patient Cohort Study REALTRK},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {8},
  doi = {10.1200/po-26-00283}
}
Kostenlos starten →